Form 8-K - Current report:
SEC Accession No. 0001493152-22-015663
Filing Date
2022-06-02
Accepted
2022-06-02 09:10:15
Documents
16
Period of Report
2022-05-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47332
2 ex10-1.htm EX-10.1 82237
3 ex10-2.htm EX-10.2 116293
4 ex99-1.htm EX-99.1 25106
5 ex99-1_001.jpg GRAPHIC 1941
  Complete submission text file 0001493152-22-015663.txt   496883

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qlgn-20220526.xsd EX-101.SCH 2968
7 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qlgn-20220526_lab.xml EX-101.LAB 34240
8 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qlgn-20220526_pre.xml EX-101.PRE 22365
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3497
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

IRS No.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 22989362
SIC: 2834 Pharmaceutical Preparations